Incepta began its operation with a handful of highly skilled and dedicated professionals guided by an able leadership. Proper strategic planning, technical excellence, swift and timely decisions helped us achieve our objectives leading to much faster growth. Incepta was able to anticipate the need of the market and provide the right product at the right time. High focus on R&D investment from the very beginning made possible the introduction of quality products ahead of its competitors in most cases.
Incepta Pharmaceuticals Ltd. is now the 2nd largest company of the country and recognized as the fastest growing of the top five manufacturing company in the country. Established in the year 1999, the company has come a long way.
Currently the Zirabo and Dhamrai plant consists of several buildings with state of the art technology. There are dedicated cephalosporin manufacturing building, a specialized manufacturing building for the production of lyophilized products, insulin and amino acids and liquid and semisolid manufacturing building and also large warehouse in those facilities.
Currently all the products are coming from these two plant at Zirabo and Dhamrai. The company now produces almost all types of dosage forms covering nearly all therapeutic area.
Incepta now has one of the largest and competent sales force and large distribution network of its own, operated from 28 depots different locations throughout the country. A most dynamic skilled and dedicated marketing team comprising of pharmacists and doctors are at the core of the marketing operation. These highly skilled professionals play a crucial role in providing the necessary strategic guideline for the promotion of its product.
Chronology of Events
CORRECTING and REPLACING DKT WomanCare and Incepta Pharmaceuticals Ink Strategic Deal to Expand Markets, Scale Up Access to World-Class Injectable Contraceptive in 40 Countries
Our Growth In Comparison With Local Pharma Market (IMS* Data)
From the very beginning Incepta has focused on launching newer and innovative products. High investment in R&D and advanced technology has allowed the company to launch approximately more than 600 generics, more than 1300 preparations, 295 which were "first ever in Bangladesh". Incepta and its sister concerns are now manufacturing Human vaccines, Monoclonal antibodies, Biotech products, Hormones, Natural products, Animal health products, Hygiene products and Hospital devices in wide range of dosage forms. Acceptance of these high quality products led to the company caring 2nd position among Pharma companies within 8 years of starting operation.
| Year | No. of Products | First Ever Product | IMS Rank* |
|---|---|---|---|
| 2023 | 1100 + | 14 | 2nd |
| 2022 | 1000 + | 14 | 2nd |
| 2021 | 1000 + | 12 | 2nd |
| 2020 | 900 + | 22 | 2nd |
| 2019 | 870 | 33 | 2nd |
| 2018 | 865 | 21 | 2nd |
| 2017 | 810 | 5 | 2nd |
| 2016 | 783 | 14 | 2nd |
| 2015 | 742 | 5 | 2nd |
| 2014 | 706 | 3 | 2nd |
| 2013 | 686 | 7 | 2nd |
| 2012 | 631 | 6 | 2nd |
| 2011 | 632 | 9 | 2nd |
| 2010 | 594 | 10 | 2nd |
| 2009 | 585 | 4 | 2nd |
| 2008 | 532 | 10 | 2nd |
| 2007 | 451 | 17 | 3rd |
| 2006 | 368 | 9 | 3rd |
| 2005 | 288 | 27 | 3rd |
| 2004 | 198 | 6 | 5th |
| 2003 | 154 | 18 | 8th |
| 2002 | 119 | 14 | 10th |
| 2001 | 78 | 11 | 12th |
| 2000 | 35 | 4 | 31st |
* Intercontinental Marketing Services (IMS)